Alaunos Therapeutics
TCRT
29 hedge funds and large institutions have $623K invested in Alaunos Therapeutics in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 21 reducing their positions, and 24 closing their positions.
10.5% more ownership
Funds ownership: 1.51% → 12% (+10%)
42% less funds holding
Funds holding: 50 → 29 (-21)
63% less capital invested
Capital invested by funds: $1.69M → $623K (-$1.07M)
88% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 24
95% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$255 |
| 2 |
BF
BOK Financial
Tulsa,
Oklahoma
|
+$237 |
| 3 |
HI
Harbour Investments
Madison,
Wisconsin
|
+$165 |
| 4 |
CCM
Chilton Capital Management
Houston,
Texas
|
+$57 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$63.1K |
| 2 |
State Street
Boston,
Massachusetts
|
-$35.1K |
| 3 |
CB
Commerce Bank
Kansas City,
Missouri
|
-$20.4K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$20.3K |
| 5 |
SA
Sanctuary Advisors
Indianapolis,
Indiana
|
-$16.2K |
TCRT Hedge Fund Activity: Q3 2024 in Review
29 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q3 2024, worth a combined $623K — down 63% from $1.69M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of TCRT and 3 opened new positions — a net loss of 21 holders — while 21 trimmed existing stakes and 1 added.
The largest buyer was Bank of America, adding an estimated $255. The largest seller was Vanguard Group, cutting an estimated $63.1K.
- 29 institutional investors held Alaunos Therapeutics (TCRT) as of Q3 2024, down from 50 in Q2 2024.
- Funds reported $623K of Alaunos Therapeutics stock for Q3 2024, down 63% quarter-over-quarter.
- 3 funds opened new Alaunos Therapeutics positions in Q3 2024 and 24 closed out, a net change of -21 holders.
- The largest Alaunos Therapeutics buyer in Q3 2024 was Bank of America, an estimated $255 added.
- The largest Alaunos Therapeutics seller in Q3 2024 was Vanguard Group, an estimated $63.1K sold.
Based on aggregated 13F filings for Q3 2024.